Workshop: microRNA Research & Immunology

by Christoph on May 7, 2015

in Workshops

microRNA-Immunology-WorkshopIf you are traveling to New Orleans to attend IMMUNOLOGY 2015 you might be interested in the following workshop next Monday, May 11th:

Recent Work & Current Methods in Immunology microRNA Research

May 11, 2015 – 11:15 AM-12:00 PM – Exhibit Hall Workshop Room #1

There is now strong evidence suggesting that miRNA signaling plays a significant role in both innate and adaptive immune responses and their dysregulation contributes to pathogenesis.  This workshop presented by LC Sciences and Norgen Biotek will focus on the recent developments of microRNA research in the field of immunology and current methods for microRNA isolation and profiling including next-gen sequencing.

  • Recent developments of microRNA research in the field of immunology
  • Current methods for microRNA isolation and profiling
  • Case studies and application examples

Bernard Lam, Ph.D., Senior Research Scientist, Norgen Biotek
Christoph Eicken, Ph.D., Head of Technical Services, LC Sciences



Series D is Mirna’s Largest Financing to Date With Ten Institutional and Strategic Investors

miRNA Therapeutics Inc. LogoAUSTIN, TX–(Marketwired – April 30, 2015) - Mirna Therapeutics (Mirna), a private, clinical-stage biopharmaceutical and immuno-oncology company focused on the development of microRNA-based cancer therapeutics, today announced the completion of a $41.8 million Series D financing. The company’s second institutional financing was led by Baxter Ventures, joined by other new investors, Eastern Capital, Santé Ventures, Morningside Ventures, Rock Springs Capital, and Celgene Corporation. Existing investors Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners, Correlation Ventures, and others, also participated in the financing. The funding will enable Mirna to advance its lead microRNA (miRNA) therapeutic product candidate, MRX34, into Phase 1b and Phase 2 trials in 2016. Indications for further development will be selected at the completion of Mirna’s ongoing Phase 1 trial in patients with hepatocellular carcinoma, other solid tumors and hematological malignancies. The Company also plans to advance a second miRNA therapeutic candidate into clinical trials with the proceeds of this financing, as well as embark on a combination therapy development program.

“Mirna is the industry leader in microRNA Replacement Therapy and we are excited to have the opportunity to invest,” said Geeta Vemuri, Vice President and Head of Baxter Ventures. “The Company has generated [click to continue…]


somagenics_logoSANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ – SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA.

There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression profiling and diagnostic purposes. There are many advantages to using NGS, including unlimited multiplexing, high sensitivity, sequence specificity and ability to detect miRNA sequence editing.  Targeted NGS brings these advantages to the quantification of any specific group of sequences of interest.  However, sequence bias in the construction of the small RNA libraries used in sequencing has so far limited the utility of NGS, both targeted and non-targeted. This bias gives distorted small RNA profiles and renders some species of RNA that might be good biomarkers unavailable for accurate quantification.

“RealSeq–T improves the accuracy and sensitivity of targeted NGS compared to current methods and provides accurate quantification of all miRNA species of interest,” said Dr. Brian Johnston, CEO of SomaGenics.  “We are excited [click to continue…]


-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-

-RG-125 (AZD4076) is Regulus’ 3rd Clinical Candidate, Achieving Key ‘Clinical Map Initiative’ Goal for 2015-

regulus therapeutics logoLA JOLLA, Calif., April 7, 2015 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107″) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.  RG-125 (AZD4076) is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application.  In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 (AZD4076) program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 (AZD4076) in humans by the end of 2015.

“Regulus is very pleased that AstraZeneca has chosen to advance a microRNA therapeutic candidate from this exciting program toward the clinic.  RG-125 acts as a novel insulin sensitizer which we believe may inform a differentiated development path to treat patients with complicated metabolic disorders,” said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.  “RG-125 represents our third clinical development candidate to arise from our novel technologies in less than two years, which confirms the productivity of our platform, achieves a key goal under our ‘Clinical Map Initiative’, and underscores our leadership in the microRNA therapeutics field.”

Marcus Schindler, Head of Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca, said: “This is a tremendous achievement for our collaboration and an exciting step for AstraZeneca to be [click to continue…]


Regulus Receives Orphan Medicinal Product Designation from the European Commission for RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome

regulus therapeutics logoLA JOLLA, Calif., March 25, 2015 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 (“miR-21″) for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In July 2014, the U.S. Food & Drug Administration granted orphan drug designation to RG-012 for the treatment of Alport syndrome.

“We are pleased to have received orphan medicinal product designation in the European Union for RG-012, a key microRNA therapeutic program under our ‘Clinical Map Initiative’,” said Paul Grint, M.D., Chief Medical Officer of Regulus. “Alport syndrome is a life threatening disease and patients have very limited treatment options because there is currently no approved therapy.  We believe that RG-012 represents an opportunity to make a significant impact in the lives of patients with Alport syndrome and we look forward to advancing this program into the clinic.”

Regulus is currently enrolling patients in a natural history of disease study called ATHENA to gather information about the changes in renal function over time in patients with Alport syndrome.  Data from [click to continue…]


Atheroprotective miRNA Signaling Pathways

January 22, 2015

MicroRNA (miRNA) are continually being identified as essential regulators of gene expression in a wide variety of different cellular contexts. A study published in March of 2012 in Nature Cell Biology1 identified an atheroprotective miRNA signaling pathway in which the miR-143/145 gene cluster is upregulated in endothelial cells and transferred to underlying smooth muscle cells […]

Read the full article →

Abcam acquires Firefly BioWorks to expand capabilities in multiplex analysis

January 22, 2015

Cambridge UK, 21 January, 2015: Abcam plc, a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of Firefly BioWorks Inc (“Firefly”) (“the Acquisition”) on a cash-free/debt-free basis for £18.5m ($28.0m). The consideration, which is payable in […]

Read the full article →

Regulus Aims to Advance microRNA Therapeutics Portfolio and Regulus microMarkersSM Division

January 8, 2015

Regulus Announces Key Goals Under its ‘Clinical Map Initiative’ for 2015 Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015 LA JOLLA, Calif., Jan. 8, 2015 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical […]

Read the full article →

SomaGenics Receives $2,275,000 in NIH Funding to Develop its RNAi Therapeutics and microRNA Technologies

December 18, 2014

SANTA CRUZ, Calif., Dec. 18, 2014 /PRNewswire/ — SomaGenics has recently been awarded $2,275,000 in Small Business Innovation Research (SBIR) grants from the NIH to further develop and expand its RNA-based technologies in the areas of wound healing, hepatitis delta virus (HDV) therapeutics, microRNA (miRNA) expression profiling, and next-generation sequencing. SomaGenics’ wound healing program is […]

Read the full article →

Novel Biomarkers for Drug-induced Liver Injury

December 12, 2014

MicroRNAs have emerged as promising biomarkers of organ damage including injury of the liver. In this study the new generation of high-throughput sequencing technology was applied to detect circulating  miRNAs in serum from patients with accidental acetaminophen overdose and identified a set of 33 known miRNAs and 3 novel miRNA-like small RNAs that are functionally […]

Read the full article →